Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05232071 · ClinicalTrials.gov registry record · Phase 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Inventiva Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT05232071 is a Phase 2 study that has completed, run by Inventiva Pharma. The registered enrollment target is 42 participants.
The verdict
NCT05232071, a Phase 2 study, has completed, sponsored by Inventiva Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
Interventions
- DRUG Placebo
- DRUG Empagliflozin
- DRUG IVA337
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2024-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05232071
The ClinicalTrials.gov registry entry for NCT05232071 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inventiva Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05232071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05232071 about?
NCT05232071 is a clinical study titled "Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus". The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
What is the current status of trial NCT05232071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2022-06-29. Estimated completion is 2024-06-04.
What interventions are being tested in trial NCT05232071?
The interventions under investigation include: Placebo (DRUG), Empagliflozin (DRUG), IVA337 (DRUG).
Who is sponsoring clinical trial NCT05232071?
This trial is sponsored by Inventiva Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.